For research use only. Not for therapeutic Use.
TUPS is a soluble epoxide hydrolase (sEH) inhibitor with an IC50 value of 3 nM for recombinant human sEH. TUPS prevents isoproterenol (ISO)-induced cardiac hypertrophy.
KEYWORDS: TUPS | supplier | sEH inhibitor | CAS [950184-27-7] | Eicosanoid epoxides | sEH | Inhibitor | Enzymes | Cardiac hypertrophy | Hypertension | Analgesia
| Catalog Number | I037619 |
| CAS Number | 950184-27-7 |
| Molecular Formula | C14H18F3N3O4S |
| Purity | ≥95% |
| IUPAC Name | 1-(1-methylsulfonylpiperidin-4-yl)-3-[4-(trifluoromethoxy)phenyl]urea |
| InChI | InChI=1S/C14H18F3N3O4S/c1-25(22,23)20-8-6-11(7-9-20)19-13(21)18-10-2-4-12(5-3-10)24-14(15,16)17/h2-5,11H,6-9H2,1H3,(H2,18,19,21) |
| SMILES | CS(=O)(=O)N1CCC(CC1)NC(=O)NC2=CC=C(C=C2)OC(F)(F)F |
| Reference | N Chiamvimonvat et al. The soluble epoxide hydrolase as a pharmaceutical target for hypertension. J Cardiovasc Pharmacol. 2007 Sep;50(3):225-37. B Inceoglu et al. Analgesia mediated by soluble epoxide hydrolase inhibitors is dependent on cAMP. Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):5093-7. H Zhang et al. Soluble epoxide hydrolase inhibitor, TUPS, attenuates isoproterenol/angiotensin II-induced cardiac hypertrophy through mammalian target of rapamycin-mediated autophagy inhibition. J Pharm Pharmacol. 2019 Aug;71(8):1291-1300. |
